Big Buttons

• FDA doubles down: Tirzepatide is off shortage

  ...but that doesn't mean the issue is completely settled. read more →

• A couple of state updates

  Good news from Alabama, but a problem in Massachusetts read more →

• Defending GLP-1 compounding

  The latest letters APC's been sending to oppose efforts to restrict compounding read more →

• Thumbs-up for FDA crackdown

  APC was thrilled when the FDA announced it was taking action against illegal online businesses claiming to sell “research-grade” compounds. read more →

• A PANS/PANDAS explainer

  For your patients: Information about a couple of underdiagnosed pediatric mental health conditions read more →

• What, a year?

  In the final board chair column of the year, here are our top 7 accomplishments in 2024. read more →

• “Simply not a rational approach to regulating an industry”

  This week APC offered its final (and pointed) suggestions to the California Board of Pharmacy on their proposed significant – and we would say unjustified – changes to their compounding regulations. read more →

• Get a cease and desist letter from Verrica?

  APC has heard reports from several pharmacies that have received them — here's what to know. read more →

More News

Semaglutide, tirzepatide, and more:
Important background information on GLP-1 compounding

• GLP-1 Compounding Primer (2-page PDF)
• APC’s detailed statement on shortage drug compounding and GLP-1s
• Compounded GLP-1 reporting: Our CEO’s commentary
• Issue Brief: Compounded GLP-1 Drugs and Patient Adverse Events
• Guidance we give our members:
  “Best Practices for Marketing Compounded Drugs“
  “Best Practices for Compounding Shortage Drugs“
• FDA’s December 19 Declaration on the Tirzepatide Shortage Status: Our CEO’s statement